Total medical devices industry M&A deals worth $3.8bn were announced globally in October 2022, led by Thermo Fisher Scientific’s $2.6bn acquisition of The Binding Site Group, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 59.4% over the previous month of $9.32bn and a drop of 48.3% when compared with the last 12-month average, which stood at $7.31bn.
Comparing M&A deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $3.74bn. At the country level, the UK topped the list in terms of deal value at $2.6bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of M&A deals activity in October 2022 was the US with 22 deals, followed by the Germany with three and Hong Kong Special Administrative Region of China with one.
In 2022, as of October, medical devices M&A deals worth $32.61bn were announced globally, marking an increase of 55.6% year on year.
medical devices industry M&A deals in October 2022: Top deals
The top five M&A deals accounted for 100% of the overall value during October 2022.
The combined value of the top five medical devices M&A deals stood at $3.78bn, against the overall value of $3.8bn recorded for the month.
The top five medical devices industry M&A deals of October 2022 tracked by GlobalData were:
1) Thermo Fisher Scientific’s $2.6bn acquisition deal with The Binding Site Group
2) The $1.14bn acquisition of M.A. Med Alliance by Cordis
3) Tivic Health Systems’s $33.5m asset transaction deal with ReliefBand Technologies
4) The $11.7m acquisition of 51% stake in Changzhou Biowin Pharmaceutical by Shineco Life Science Research
5) LOVE Pharma’s $1.46m acquisition deal with Naltrexone Therapeutics